Industry
Biotechnology
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.
Loading...
Open
3.29
Mkt cap
11M
Volume
136K
High
3.57
P/E Ratio
-0.01
52-wk high
152.40
Low
3.29
Div yield
N/A
52-wk low
1.80
Portfolio Pulse from Benzinga Newsdesk
December 28, 2023 | 3:18 pm
Portfolio Pulse from Benzinga Newsdesk
December 28, 2023 | 2:52 pm
Portfolio Pulse from Benzinga Newsdesk
December 28, 2023 | 2:48 pm
Portfolio Pulse from Benzinga Newsdesk
December 28, 2023 | 2:47 pm
Portfolio Pulse from Benzinga Newsdesk
December 28, 2023 | 2:42 pm
Portfolio Pulse from ryanfaloona@benzinga.com
December 28, 2023 | 1:42 pm
Portfolio Pulse from Avi Kapoor
December 28, 2023 | 1:22 pm
Portfolio Pulse from Benzinga Insights
December 28, 2023 | 1:07 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.